QuidelOrtho (QDEL) versus Its Peers Critical Comparison

QuidelOrtho (NASDAQ:QDEL) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its rivals? We will compare QuidelOrtho to related businesses based on the strength of its analyst recommendations, profitability, valuation, earnings, dividends, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and target prices for QuidelOrtho and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	2	4	0	0	1.67
QuidelOrtho Competitors	4279	10550	18327	829	2.46

QuidelOrtho currently has a consensus target price of $13.62, suggesting a potential upside of 27.34%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.33%. Given QuidelOrtho’s higher probable upside, equities analysts clearly believe QuidelOrtho is more favorable than its rivals.

Profitability

This table compares QuidelOrtho and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-14.24%	3.22%	1.03%
QuidelOrtho Competitors	-305.24%	-170.58%	-22.05%

Institutional and Insider Ownership

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 1.1% of QuidelOrtho shares are owned by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares QuidelOrtho and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
QuidelOrtho	$2.73 billion	-$1.13 billion	-1.98
QuidelOrtho Competitors	$1.88 billion	$138.79 million	10.35

QuidelOrtho has higher revenue, but lower earnings than its rivals. QuidelOrtho is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

QuidelOrtho has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, QuidelOrtho’s rivals have a beta of 2.56, indicating that their average stock price is 156% more volatile than the S&P 500.

Summary

QuidelOrtho rivals beat QuidelOrtho on 7 of the 13 factors compared.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.